Medicus Pharma (MDCX) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $3.25, -5.25% vs the prior close of $3.43.
- Volume 28.18K shares, 0.2x its 50-day average (light).
- New SEC filings: 424B3 (Oct 16, 2026), 8-K (Oct 16, 2026), SCHEDULE 13G/A (Oct 16, 2026).
- No new insider buys or sales reported since the prior session.
MDCX slides 5.2% to $3.25. Closed at $3.25, -5.25% vs the prior close of $3.43. Day range $3.25–$3.61, opened at $3.61.
MDCX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — MDCX slides 5.2% to $3.25
- Closed at $3.25, -5.25% vs the prior close of $3.43. Day range $3.25–$3.61, opened at $3.61.
- Volume was 28.18K shares, 0.2x its 50-day average of 121.97K — lighter than usual.
- Price is -66.7% vs its 50-day average ($9.77) and -87.8% vs its 200-day average ($26.56).
- 52-week range $2.92–$139.00; today's close sits at 0% of that range, 97.7% below the 52-week high.
Oct 15, 2026 — MDCX jumps 9.9% to $3.43
- Closed at $3.43, +9.94% vs the prior close of $3.12. Day range $3.00–$3.65, opened at $3.09.
- Volume was 202.90K shares, 1.7x its 50-day average of 118.58K.
- Price is -65.8% vs its 50-day average ($10.02) and -87.3% vs its 200-day average ($26.92).
- 52-week range $2.92–$139.00; today's close sits at 0% of that range, 97.5% below the 52-week high.
Oct 14, 2026 — MDCX slides 4.9% to $3.12, a 52-week low, 5 down days in a row
- Closed at $3.12, -4.88% vs the prior close of $3.28. Day range $2.92–$3.25, opened at $3.08.
- Volume was 68.00K shares, 0.6x its 50-day average of 117.79K — lighter than usual.
- Price is -69.5% vs its 50-day average ($10.24) and -88.6% vs its 200-day average ($27.27).
- 52-week range $2.92–$139.00; today's close sits at 0% of that range, 97.8% below the 52-week high.
- That makes 5 straight losses.
Oct 13, 2026 — MDCX slides 8.4% to $3.28, a 52-week low, 4 down days in a row
- Closed at $3.28, -8.38% vs the prior close of $3.58. Day range $3.14–$3.67, opened at $3.54.
- Volume was 66.00K shares, 0.6x its 50-day average of 118.17K — lighter than usual.
- Price is -68.7% vs its 50-day average ($10.49) and -88.1% vs its 200-day average ($27.65).
- 52-week range $3.14–$139.00; today's close sits at 0% of that range, 97.6% below the 52-week high.
- That makes 4 straight losses.
Oct 12, 2026 — MDCX slides 22.2% to $3.58, a 52-week low, 3 down days in a row
- Closed at $3.58, -22.17% vs the prior close of $4.60. Day range $3.58–$4.69, opened at $4.20.
- Volume was 123.20K shares, 1.0x its 50-day average of 117.38K.
- Price is -66.6% vs its 50-day average ($10.72) and -87.2% vs its 200-day average ($28.02).
- 52-week range $3.58–$139.00; today's close sits at 0% of that range, 97.4% below the 52-week high.
- That makes 3 straight losses.
Oct 9, 2026 — MDCX slides 9.8% to $4.60, a 52-week low on 3.1x normal volume
- Closed at $4.60, -9.80% vs the prior close of $5.10. Day range $4.20–$4.75, opened at $4.35.
- Volume was 346.64K shares, 3.1x its 50-day average of 111.09K — unusually heavy trading.
- Price is -57.9% vs its 50-day average ($10.92) and -83.8% vs its 200-day average ($28.38).
- 52-week range $4.20–$139.00; today's close sits at 0% of that range, 96.7% below the 52-week high.
Oct 8, 2026 — MDCX slides 36.3% to $5.10, a 52-week low on 2.8x normal volume
- Closed at $5.10, -36.25% vs the prior close of $8.00. Day range $4.70–$5.80, opened at $5.75.
- Volume was 291.21K shares, 2.8x its 50-day average of 105.73K — unusually heavy trading.
- Price is -54.0% vs its 50-day average ($11.10) and -82.3% vs its 200-day average ($28.75).
- 52-week range $4.70–$139.00; today's close sits at 0% of that range, 96.3% below the 52-week high.
Oct 7, 2026 — MDCX rises 0.6% to $8.00
- Closed at $8.00, +0.63% vs the prior close of $7.95. Day range $8.00–$8.15, opened at $8.00.
- Volume was 95.73K shares, 0.9x its 50-day average of 104.63K.
- Price is -29.0% vs its 50-day average ($11.26) and -72.5% vs its 200-day average ($29.14).
- 52-week range $7.20–$139.00; today's close sits at 1% of that range, 94.2% below the 52-week high.
- SEC filings that day: 8-K.
Oct 6, 2026 — MDCX slides 4.8% to $7.95
- Closed at $7.95, -4.79% vs the prior close of $8.35. Day range $7.90–$8.45, opened at $8.25.
- Volume was 21.08K shares, 0.2x its 50-day average of 105.56K — lighter than usual.
- Price is -30.2% vs its 50-day average ($11.38) and -73.1% vs its 200-day average ($29.52).
- 52-week range $7.20–$139.00; today's close sits at 1% of that range, 94.3% below the 52-week high.
Oct 5, 2026 — MDCX jumps 3.7% to $8.35
- Closed at $8.35, +3.73% vs the prior close of $8.05. Day range $7.75–$8.55, opened at $8.30.
- Volume was 34.10K shares, 0.3x its 50-day average of 105.29K — lighter than usual.
- Price is -27.7% vs its 50-day average ($11.54) and -72.1% vs its 200-day average ($29.90).
- 52-week range $7.20–$139.00; today's close sits at 1% of that range, 94.0% below the 52-week high.
Oct 2, 2026 — MDCX rises 2.5% to $8.05
- Closed at $8.05, +2.55% vs the prior close of $7.85. Day range $7.75–$8.20, opened at $7.80.
- Volume was 20.78K shares, 0.2x its 50-day average of 105.22K — lighter than usual.
- Price is -31.5% vs its 50-day average ($11.74) and -73.4% vs its 200-day average ($30.31).
- 52-week range $7.20–$139.00; today's close sits at 1% of that range, 94.2% below the 52-week high.
MDCX latest news & SEC filings
Every SEC filing by or about MDCX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 16, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Oct 16, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 3.03 — Change to shareholder rights.
- Item 5.03 — Amended its charter or bylaws / changed fiscal year.
Oct 16, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Oct 7, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Oct 7, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 14, 2026 · Form SCHEDULE 13D — Activist-style stake (13D)
Activist-style stake (13D) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 14, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.02 — Ended a material agreement.
Sep 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 3.02 — Sold unregistered shares.
Sep 8, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 8, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 8, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 8, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 8, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 3, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Things to know before you trade MDCX
- How much it moves: over the last 20 sessions the average daily move was 6.44% (largest 36.3%). That is a volatile stock.
- Liquidity: about 83.74K shares (≈$272.15K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $3.25 vs a range of $2.92–$139.00 (0% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:50 on Oct 12, 2026
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 8-K Oct 16, 2026; 8-K Oct 7, 2026; 8-K Sep 14, 2026.
- Share count: 63.18M shares outstanding (Aug 10, 2026), +254.6% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
MDCX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 3.61 | 3.61 | 3.25 | 3.25 | 28.18K |
| Oct 15, 2026 | 3.09 | 3.65 | 3.00 | 3.43 | 202.90K |
| Oct 14, 2026 | 3.08 | 3.25 | 2.92 | 3.12 | 68.00K |
| Oct 13, 2026 | 3.54 | 3.67 | 3.14 | 3.28 | 66.00K |
| Oct 12, 2026 | 4.20 | 4.69 | 3.58 | 3.58 | 123.20K |
| Oct 9, 2026 | 4.35 | 4.75 | 4.20 | 4.60 | 346.64K |
| Oct 8, 2026 | 5.75 | 5.80 | 4.70 | 5.10 | 291.21K |
| Oct 7, 2026 | 8.00 | 8.15 | 8.00 | 8.00 | 95.73K |
| Oct 6, 2026 | 8.25 | 8.45 | 7.90 | 7.95 | 21.08K |
| Oct 5, 2026 | 8.30 | 8.55 | 7.75 | 8.35 | 34.10K |
| Oct 2, 2026 | 7.80 | 8.20 | 7.75 | 8.05 | 20.78K |
| Oct 1, 2026 | 7.90 | 8.10 | 7.65 | 7.85 | 22.65K |
| Sep 30, 2026 | 7.90 | 8.40 | 7.75 | 8.05 | 36.32K |
| Sep 29, 2026 | 7.55 | 7.95 | 7.50 | 7.85 | 28.15K |
| Sep 28, 2026 | 7.55 | 7.80 | 7.35 | 7.60 | 30.45K |
| Sep 25, 2026 | 8.00 | 8.00 | 7.50 | 7.60 | 42.01K |
| Sep 24, 2026 | 8.25 | 8.25 | 7.75 | 7.95 | 54.89K |
| Sep 23, 2026 | 8.00 | 8.15 | 7.75 | 7.95 | 30.00K |
| Sep 22, 2026 | 8.40 | 8.50 | 7.85 | 8.20 | 73.54K |
| Sep 21, 2026 | 8.50 | 8.80 | 8.30 | 8.55 | 58.92K |
About Medicus Pharma
Medicus Pharma (MDCX) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in W. CONSHOHOCKEN, PA. State of incorporation: Ontario, Canada. Fiscal year ends December 31. SEC CIK 1997296.
MDCX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| William Ashton | Director | Jun 4, 2026 |
| Raza Bokhari | Chief Executive Officer | Sep 8, 2026 |
| Robert J. Ciaruffoli | Director | Jun 4, 2026 |
| Barry Fishman | Director | Jun 4, 2026 |
| Larry Kaiser | Director | Jun 4, 2026 |
| Patrick J Mahaffy | Director | Jun 4, 2026 |
| Sara R. May | Director | Jun 4, 2026 |
| Ajay Raju | Director | Jun 4, 2026 |
| Cathy Mcmorris Rodgers | Director | Jun 4, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Raza Bokhari | Chief Executive Officer | Sep 8, 2026 |
| Carolyn F. Bonner | President and CFO | Sep 8, 2026 |
| Edward J. Brennan | Chief Scientific Officer | Sep 8, 2026 |
| Faisal Mehmud | Chief Medical Officer | Sep 8, 2026 |
| Andrew Alasdair Smith | Chief Operating Officer | Sep 8, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
MDCX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-47.28M | -2.74 | $-22.78M |
| Dec 31, 2024 | — | $-11.16M | -1.16 | $-10.25M |
| Dec 31, 2023 | — | $-5.31M | -1.53 | $-4.16M |
Latest balance sheet: total assets $27.12M, total liabilities $28.84M, cash $15.17M (as of Jun 30, 2026).
MDCX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| No 8-K earnings releases in recent filings. | ||
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on MDCX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.